Outcomes of epilepsy and assessment of risk factors for patients
Abstract
Background Epilepsy is a common and widely recognized neurological problem, but it tends to be poorly understood, misdiagnosed, and inadequately treated. Objective: Our study aimed to assess epilepsy findings and determine risk factors affecting patients with epilepsy. Patients and methods A total of 90 participating samples of epilepsy patients who have ages between 20 – 70 years were recruited. Patient data were collected randomly from different hospitals in Iraq through patient interviews and review of medical records. This study evaluated the outcomes of epilepsy patients in terms of pain rate and quality of life for patients who were followed for one year from the period July 2022 to July 2023. Furthermore, we conducted a logistic regression analysis of the risk factors affecting the outcomes of epilepsy patients. Results Our findings showed that patients who age (61 − 70) years which are the most class with 45.56% of cases, males had 54 cases and females had 36 cases, patients who have BMI > 30.5 were the highest, which include 36 cases, patients have hypertension with 59 cases, and diabetes with 24 cases, 50 patients had sleep duration within 8 - 10 hours and 40 patients had sleep disorder. In assessment of patients’ general health were excellent with 10 cases, very good/good with 24 cases, and fair/poor with 56 cases. Conclusion Older, single, and have sleep disorders are more likely to get epilepsy. Moreover, epilepsy risk is lower among those in very good general health.
References
2. Fisher R, et al. ILAE Official Report: A practical clinical definition of epilepsy. Epilepsia. 2014;55:475–482.
3. Fisher R, et al. Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) Epilepsia. 2005;46:470–472.
4. Nunes V, Sawyer L, Neilson J, Sarri G, Cross J. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ. 2012;344:e281–e281.
5. Singh A, Trevick S. The Epidemiology of Global Epilepsy. Neurologic Clinics. 2016;34:837–847.
6. De Boer H, Mula M, Sander J. The global burden and stigma of epilepsy. Epilepsy & Behavior. 2008;12:540–546.
7. Prilipko, L. Atlas Epilepsy care in the world 2005. (World Health Organization, 2005).
8. WHO. Epilepsy in The Who African Region: Bridging the Gap. (World Health Organization, 2004).
9. Tekle-Haimanot R, et al. Attitudes of rural people in central Ethiopia toward epilepsy. Social Science & Medicine. 1991;32:203–209.
10. Tekle- Haimanot R, et al. Community-Based Study of Neurological Disorders in Rural Central Ethiopia. Neuroepidemiology. 1990;9:263–277.
11. Wilson SJ, et al. Indications and expectations for neuropsychological assessment in routine epilepsy care: Report of the ILAE Neuropsychology Task Force, Diagnostic Methods Commission, 2013-2017. Epilepsia. 2015;56:674–81.
12. Sillanpää M, Schmidt D. Long-term outcome of medically treated epilepsy. Seizure. 2017;44:211–6.
13. Kwan P, Schachter SC, Brodie MJ. Drug-Resistant Epilepsy. N. Engl. J. Med. 2011;369:919–26.
14. Tefera GM, Woldehaimanot TE, Angamo MT. Poor treatment outcomes and associated factors among epileptic patients at Ambo Hospital, Ethiopia. Gaziantep Medical Journal. 2015;21:9–16.
15. Dua T, De Boer HM, Prilipko LL, Saxena S. Epilepsy care in the world: Results of an ILAE/IBE/WHO Global Campaign Against Epilepsy survey. Epilepsia. 2006;47:1225–31.
16. Scott RA, Lhatoo SD, Sander JW. The treatment of epilepsy in developing countries: Where do we go from here? World Heal. Organ. Bull. World Heal. Organ. 2001;79:344–51.
17. Jones RM, Butler JA, Thomas VA, Peveler RC, Prevett M. Adherence to treatment in patients with epilepsy: Associations with seizure control and illness beliefs. Seizure. 2006;15:504–8.
18. Mbuba CK, Ngugi AK, Newton CR, Carter JA. The epilepsy treatment gap in developing countries: A systematic review of the magnitude, causes, and intervention strategies. Epilepsia. 2008;49:1491–503.
19. Hovinga CA, et al. Association of non-adherence to antiepileptic drugs and seizures, quality of life, and productivity: Survey of patients with epilepsy and physicians. Epilepsy Behav. 2008;13:316–22.
20. Shen C, et al. Factors predictive of late remission in a cohort of Chinese patients with newly diagnosed epilepsy. Seizure. 2016;37:20–4.
21. Mohanraj R, Brodie MJ. Early predictors of outcome in newly diagnosed epilepsy. Seizure. 2013;22:333–44.
22. So, EL. Predictors of outcome in newly diagnosed epilepsy: Clinical, EEG and MRI. Neurol. Asia. 2011;16:27–9.
23. Sperling MR. The Consequences of Uncontrolled Epilepsy. CNS Spectr. 2004;9:98–109.
24. Laxer KD, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav. 2014;37:59–70.
25. Fanta T, Azale T, Assefa D, Getachew M. Prevalence and factors associated with perceived stigma among patients with epilepsy in Ethiopia. Psychiatry journal. 2015;201:1–7.
26. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol. Health. 1999;14:1–24.
27. Mostafavi F, Najimi A, Sharifirad G, Golshiri P. Beliefs About Medicines in Patients with Hypertension: The Instrument Validity and Reliability in Iran. Mater. Socio. Medica. 2016;28:298.
28. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med. Care. 1986;24:67–74.
29. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub (2013).
30. Manford M. Recent advances in epilepsy. J. Neurol. 2017;264:1811–24.
